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Thrombolysis for Acute Stroke: The Incontrovertible,
the Controvertible, and the Uncertain
Arguments concerning the usefulness of thrombolytic
treatments in the emergency treatment of patients
with acute ischemic strokes have become common-
place. Unfortunately, much of the debate in the
emergency medicine community has become mired
in the posturing of critics and advocates, impeding
a meaningful exploration of the issues involved.
Positions on either side have become inflexible, trans-
forming the debate into a ‘‘win-lose’’ proposition,
without hope of identifying the truth. Approaching
this debate with a review of what we know, and do
not know, is thereby warranted. Furthermore, a con-
sideration of how physicians adopt new therapies
may provide insight into the limited acceptance
fibrinolytic treatment in stroke has achieved.
THE INCONTROVERTIBLE
Much of the pathophysiology of stroke is well un-
derstood and incontrovertible. Acute stroke symp-
toms are most often caused by a focal impairment of
blood flow in a specific cerebrovascular distribution.
The impairment is usually caused by a mechanical
obstruction of flow of a thromboembolic nature.1 If
blood flow is restored within a sufficiently early time
frame, there is functional recovery of the ischemic
territory; if not, the ischemic tissue fails to recover
following reperfusion.2–6 Lastly, tissue plasminogen
activator (tPA) promotes lysis of thrombi and reper-
fusion following vascular occlusion.7,8
Each of these elements has been demonstrated
extensively in animal research and in observational
and interventional clinical research. Indeed, they are
a part of most clinicians everyday experience in
patients they have cared for with transient ischemic
attacks and in patients treated with thrombolytic
agents for coronary occlusions. Thus, the use of rapid
thrombolysis to reverse or ameliorate the effects
of acute cerebrovascular occlusion is conceptually
sound.
It would be incorrect, then, to consider the series
of clinical trials of thrombolysis in stroke,9–16 using
different agents and different treatment protocols, as
a cumulative attempt to prove the concept of throm-
bolytic therapy in stroke. Rather, the trials represent
competing attempts to identify the details of imple-
mentation: the clinical parameters in which this
concept might translate into patient benefit. In this
context, it is expected that some trials would be
negative and others positive. Hence, the conflicting
data from these trials are not surprising and do not
suggest ambiguity in the soundness of the underlying
concept of thrombolytic use in stroke.
THE CONTROVERTIBLE
The question then is in the details of implementation.
The purpose of clinical trials involving use of fibrino-
lytic treatment in stroke is to determine a set of
specific conditions in which a therapy can be effective.
Whether the existing National Institute of Neurolog-
ical Disorders and Stroke (NINDS) clinical trial ex-
perience sufficiently defines such a set of details is
potentially controvertible and therefore worthy of
review.
In the NINDS trial, 624 patients with symptoms of
acute ischemic stroke were randomly assigned to
treatment with tPA or placebo within three hours of
symptom onset. Three months later, 133 of the 312
patients (43%) treated with tPA were neurologically
intact as compared with 83 of the 312 patients (27%)
receiving placebo. Fifty-three patients (17%) treated
with tPA and 66 patients (21%) receiving placebo had
died. Twenty patients (6.4%) treated with tPA and two
patients (0.6%) receiving placebo developed symp-
tomatic intracranial hemorrhage within 36 hours of
treatment.9
Thus, in the NINDS study, the effect of tPA treat-
ment on improving neurologic outcome in the entire
sample of 624 patients was positive and durable.17
Patients with intracranial hemorrhage were included
in the benefit analysis and the higher rate of good
neurologic outcomes occurred in the treated group
despite more hemorrhages, which is a point of
frequent misunderstanding. Additionally, in response
to study critics, the trial data underwent independent,
external analysis, with the results presented at the
2003 Society for Academic Emergency Medicine
annual meeting confirming benefit from treatment in
the trial. Criticisms of the statistical analysis still exist
but should not represent the core of the remaining
controversy on the use of tPA in stroke.
Other trials evaluating different sets of conditions
have not been found efficacious in improving out-
come. Table 1 lists major differences in the reported
randomized, double-blind, placebo-controlled studies
of intravenous thrombolytic use in acute stroke.
In summary, theNINDS trial demonstrated one set of
detailed circumstances in which a specific fibrinolytic
treatment was successfully applied while differing
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protocols did not. What remains most controvertible is
whether the circumstances of the NINDS trial are
externally valid and reproducible in broad clinical
practice.
Critics correctly indicate that the NINDS study was
performed by researchers with an interest and pre-
sumed expertise in the treatment of acute stroke. It is
reasonable to question whether emergency physicians
without such expertise and resources can reproduce
the same results. Supporting this view are data dem-
onstrating circumstances in which physicians have
been unable to treat patients in a manner similar to
the protocol used in the NINDS trial and data that
patients treated in such systems did poorly.18–20
Critics also rightly note the time from symptom onset
to treatment is shorter in the NINDS trial than in
current clinical practice (see Table 1) and believe this
prevents extrapolation of the results to the community
setting.
Advocates of the therapy point to data demonstrat-
ing that physicians in a variety of practice environ-
ments can treat patients in a manner similar to that
used in the NINDS trial.21–31 Proponents also believe
that most patients with ischemic stroke are accurately
identified for thrombolytic therapy.32 They suggest
that it is not surprising to find patients treated outside
of recommended guidelines and that this is modifi-
able with training and experience. Indeed, in systems
where initial experience with recombinant tPA in
stroke was negative (even abysmal), further education
and quality assurance measures have led to appro-
priate use.21,33
Ultimately, the successful reproducibility of the
NINDS protocol in widespread clinical practice re-
mains subject to judgment and interpretation. For the
time being, individual health systems and their
treating physicians together must determine if they
are capable of providing care in a manner consistent
with the set of conditions described in the NINDS
protocol and should only treat stroke patients with
tPA if they can meet these requirements.
THE UNCERTAIN
A greater uncertainty, however, lies beyond the in-
terpretation of the existing data on this topic andwithin
the realm of physician acceptance of new treatment
recommendations. Physician behavior in adopting
changes in clinical practice is clearly multifaceted and
is poorly understood.34 Translation of clinical trial
data and associated guidelines into general clinical
practice involves 1) physician awareness and familiar-
ity with data and guidelines, 2) physician agreement
with data, 3) the belief that one can deliver the therapy
effectively, 4) the personal expectation of benefit for the
patient, 5) overcoming inertia of previous practice
patterns, and 6) modifying external barriers directly
affecting physician behavior.35
Table 1. Differences in Clinical Trial Protocols for Thrombolytic Use in Stroke
Study Location Drug Dose Time (h) Exclusion Criteria
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(1991–1995)11 Italy, United Kingdom,
Portugal
Streptokinase 1.5 million units 0–6
ECASS 1





























0–6 Blood pressure; computed
tomographic evidence of
early infarct; age
rtPA = recombinant tissue plasminogen activator.
*Mean time from onset to treatment.
yMedian time from onset to treatment.
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Given these barriers to general acceptance, the
controversy surrounding the use of tPA in stroke
may represent more the result of a ‘‘perfect (barrier)
storm’’ than disagreement over the larger concept of
thrombolytic use in stroke. Specific barriers to accep-
tance of thrombolytic use include the previously
noted controversies that have resulted in divergent
recommendations from various professional organi-
zations, perceived minimal cost–benefit impact, lack
of confidence in the methods of guideline develop-
ment, and issues regarding practical delivery of tPA.
Acceptance has also been limited due to physician
aversion to the rate of hemorrhagic complications.
Because iatrogenic adverse outcomes carry a higher
emotional burden than adverse outcomes associated
with the natural history of a disease, some physicians
may require greater certainty than usual to change
their practice. Given the infrequency of treatment,
both in the community setting and within emergency
medicine training programs, it is understandable that
physicians have concerns regarding effective fibrino-
lytic delivery in stroke. Furthermore, the historic
nihilism regarding stroke care must also be overcome.
Even if the above issues have been surmounted,
considerable external barriers remain. With increasing
patient throughput pressure, lack of timely specialist
availability or support (e.g., neurology and/or radiol-
ogy), organizational constraints, patient consent issues,
limited reimbursement, and perceived increased mal-
practice liability, it becomes clear that the barriers to
broad acceptance are substantial.
THE FUTURE
Future research efforts are needed to resolve persis-
tent controversies on the use of thrombolytics in acute
stroke, but even more importantly, efforts should be
directed toward what remains unknown. Can emer-
gency physicians in the community diagnose and
treat strokes in the manner performed in the NINDS
trial? If not, what barriers keep them from doing so?
How effective is the therapy when implemented in
the community? Is the therapy effective when given to
a population of patients with a longer mean time from
onset of symptoms to treatment than the population
treated in the NINDS trial? Why are patient outcomes
sometimes poor in the early stages of implementing
a system to treat stroke patients with tPA, and what
can be done to minimize this start-up effect? How can
the emotional, medicolegal, and educational compo-
nents of physician decision making be addressed?
Can hemorrhagic complications be reduced? Are
medicolegal concerns based on facts or fears? Can
continuing medical education improve emergency
neurologic expertise? What is the impact of stroke
teams and systems on effective delivery of thrombo-
lytic therapy? Are there adjunctive therapies that may
improve outcome or extend the treatment window
when combined with thrombolytics?
In the larger perspective, stroke will always be
a medical emergency. Future interventions for treating
stroke will likely be more effective the earlier they are
started. What can we do to encourage patients to seek
care sooner? How can we respond to, transport, and
triage patients with stroke most effectively? What do
we do for the large proportion of stroke patients not
recognized and treated early enough to be candidates
for reperfusion?
The current controversy over the use of tPA in
patients with acute stroke should not be allowed to
mire emergency stroke care in a hopeless morass, but
rather should be used as an opportunity to prove that
we can learn what is needed to make this concept
and future therapies work for our patients.—Robert
Silbergleit, MD (robie@umich.edu), Phillip A. Scott, MD,
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